

Clinical-stage biotech seeks for pharmaceutical and biotechnology companies for first-in-class ECM (extracellular matrix)-targeting peptide therapy in oncology under licensing and/or co-development, academic research groups & healthcare investors

Summary

Profile type

Technology request

Company's country

France

POD reference

TRFR20260729016

Type of partnership

Research and development cooperation agreement
Investment agreement
Commercial agreement with technical assistance

Targeted countries

• Japan

Contact Person

Myrthe BONGERS

Term of validity

Last update

25 Aug 2026

General Information

Short summary

A French clinical-stage biotechnology company committed to develop therapeutic strategies towards multiple types of cancer, seeks pharmaceutical & biotechnology partners to co-develop and license a first-in-class peptide therapeutic targeting the TSP-1/CD47 axis and extracellular matrix (ECM). Their new target is currently in a Phase I/IIa clinical trial in Europe for advanced solid tumors. Collaborations with academic researchers, clinicians and specialist healthcare investors are welcome.

Full description

A French clinical-stage biotechnology company developing first-in-class peptide therapeutics targeting the extracellular matrix (ECM) and tumor microenvironment (TME).

Its lead candidate, is a novel peptide targeting the thrombospondin-1 (TSP-1)/CD47 signaling axis. Unlike conventional CD47 antibodies, it selectively modulates this pathway through TSP-1, restoring anti-tumor immunity, reversing T-cell exhaustion and normalizing tumor vasculature while potentially avoiding the hematological toxicities associated with systemic CD47 blockade.

It has demonstrated broad efficacy across several solid tumor models and its mechanism of action has recently been published in Nature Immunology. The program is currently being evaluated in a Phase I/IIa clinical trial in Europe.

Beyond the novel peptide, the company has established a proprietary extracellular matrix-targeting peptide discovery platform that has generated multiple innovative therapeutic programs in oncology and other disease areas.

The company is seeking strategic pharmaceutical and biotechnology Japanese partners interested in licensing, co-development or regional/global collaborations. They also welcome collaborations with academic research groups and clinical investigators specializing in tumor immunology, extracellular matrix biology and translational oncology, as well as discussions with specialist healthcare investors interested in innovative clinical-stage oncology companies.

Advantages and innovations

- Cancer immunotherapy
- four targeted indications: ovarian cancer, colorectal cancer, pancreatic cancer and metastatic melanoma
- Target the microenvironment of the tumor

Key biological effects observed:

- Activation of anti-tumor immunity
- Reduction of tumor vascularization
- Decreased T-cell exhaustion
- Tumor growth inhibition and improved survival in vivo

Technical specification or expertise sought

The company is looking for three complementary categories of partners:

Pharmaceutical and biotechnology companies

- Licensing or co-development opportunities for the novel peptide
- Regional or global strategic partnerships
- Clinical development and commercialization

Academic researchers and clinical investigators

- Translational oncology
- Tumor microenvironment biology
- Extracellular matrix biology
- Biomarker development
- Investigator-initiated studies

Healthcare investors

- Investors specialized in innovative oncology therapeutics supporting the next stages of clinical development and value creation.

Stage of development

Under development

IPR Status

IPR granted

IPR Notes

- **International intellectual property portfolio**
- **Additional proprietary know-how**

Sustainable Development goals

- **Goal 3: Good Health and Well-being**
- **Goal 9: Industry, Innovation and Infrastructure**

Partner Sought

Expected role of the partner

Type

- Pharmaceutical companies
- Biotechnology companies
- Universities
- Research institutes
- Comprehensive cancer centers
- Healthcare investors

Role

Strategic development partner, research collaborator or financial partner.

Tasks

- Licensing
- Co-development
- Clinical development
- Translational research
- Biomarker development
- Regional commercialization
- Strategic investment

Type of partnership

Research and development cooperation agreement

Investment agreement

Commercial agreement with technical assistance

Type and size of the partner

- **University**
- **SME 11-49**
- **R&D Institution**
- **Big company**
- **SME 50 - 249**

Dissemination

Technology keywords

- **06001013 - Medical Technology / Biomedical Engineering**
- **06002004 - Protein Engineering**
- **06001002 - Clinical Research, Trials**
- **06001003 - Cytology, Cancerology, Oncology**
- **06002002 - Cellular and Molecular Biology**

Market keywords

- **04001003 - Medical genetic engineering applications**
- **05005014 - Oncology**
- **04006 - Cellular and Molecular Biology**
- **04008 - Genetic Engineering**
- **04005 - Biochemistry / Biophysics**

Targeted countries

- **Japan**

Sector groups involved

- **Health**
- **Energy-Intensive Industries - BioChemTech**